News & Updates

Prize Recognizes Drs. Randall J. Bateman and Kanta Horie of Washington University School of Medicine in St. Louis, and Drs. Oskar Hansson and Gemma Salvadó of Lund University, Sweden

Washington University professors and C2N Diagnostics co-founders Dr. Randall Bateman and Dr. David Holtzman will receive the 2026 American Innovator Award from the Bayh-Dole Coalition in Washington, D.C., on June 3.

Some of the most important studies of potential treatments for Alzheimer’s disease rely on a group of participants who know they may never fully reap the benefits.

A network of families riddled with Alzheimer’s has given scientists a unique window on the disease. But the group’s future is uncertain amid funding cuts.

A single blood test may be able to predict when a person will develop Alzheimer’s symptoms—years before memory loss begins—according to new research from the Washington University School of Medicine in St Louis.

Scientists are trying to find out why one man has been able to stave off Alzheimer’s for nearly 25 years despite having a rare genetic mutation that doctors say essentially guaranteed he developed the disease by his late 40s or early 50s.

Jake Heinrichs is a Broadway theater electrician from Brooklyn who carries one of the early-onset genes. The disease claimed his grandmother, uncle, father and brother, all within the same age range. “Symptoms in the 40s and, and dying in 50s,” he said.

Carrie Richardson, 44, inherited a genetic mutation that caused early-onset Alzheimer’s disease. She’s participating in an Alzheimer’s research study at Washington University School of Medicine.

Scientists are searching for the secret in Doug Whitney’s biology that has protected him from dementia, hoping it could lead to ways to treat or prevent Alzheimer’s for many other people.

Washing waste from the brain is an essential function of sleep—and it could help ward off dementia

Among members of the Richardson family who carry a mutation in the PSEN1 gene, the average age when symptoms start is 39

Side effects of lecanemab are manageable, study finds

The new test could also help confirm whether Alzheimer’s or another condition is causing a person’s symptoms.

New tests of blood and spinal fluid can show how far Alzheimer’s has progressed and how fast a patient’s memory will decline.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the disease.

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer’s.

Study offers clues to treatment, prevention

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.

WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise

Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.

The DIAN and DIAN-TU are deeply saddened by the recent death of our beloved colleague, Dr. Francisco Lopera, Principal Investigator at our site in Colombia (Grupo Neurociencias de Antioquia – GNA). Alzforum offers this remembrance, highlighting the impact of Dr. Lopera’s work on the AD field.

As discussed at the Alzheimer’s Association International Conference in Philadelphia, nearly two dozen mutation carriers who took gantenerumab for eight years had half the risk of developing symptoms as did untreated controls.

Many researchers think the full promise of plaque removal lies in prevention. If plaques were abolished before they could kick off downstream pathologies such as tangles, would the disease be stopped in its tracks?

DIAN-TU is launching the DIAN-TU-003 Amyloid Removal Trial (ART) to enable continued treatment for the DIAN-TU-001 Gantenerumab Open Label Extension (OLE) participants and address questions regarding the effects of removing amyloid plaques to normal levels on cognitive symptoms, clinical progression and disease processes.

We are now pleased to announce plans to re-launch the DIAN-TU-002 Primary Prevention Trial with remternetug in collaboration with Eli Lilly and Company (Lilly).

The soaring burden of dementia threatens global health. Science is paving new paths to solutions.